The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Belousov V.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical-Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University)

Bogolepova A.N.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical-Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University)

Katunina E.A.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical-Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University)

Bulanova N.V.

Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency

Mukhin V.E.

Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency

Yudin S.M.

Center for Strategic Planning and Management of Biomedical Health Risks

Cytokine status of patients with Alzheimer’s disease

Authors:

Belousov V.V., Bogolepova A.N., Katunina E.A., Bulanova N.V., Mukhin V.E., Yudin S.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(4‑2): 5‑12

DOI: 10.17116/jnevro20251250425

Read: 1418 times

Download PDF (RU)
Contact the author
Table of contents

CYTOKINE STATUS OF PATIENTS WITH ALZHEIMER’S DISEASE
CYTOKINE STATUS OF PATIENTS WITH ALZHEIMER’S DISEASE

To cite this article:

Belousov VV, Bogolepova AN, Katunina EA, Bulanova NV, Mukhin VE, Yudin SM. Cytokine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(4‑2):5‑12. (In Russ.)
https://doi.org/10.17116/jnevro20251250425

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
The effect of the iron III poly­saccharide complex use on the cyto­kines, natriuretic peptide and erythropoietin levels in patients with chro­nic heart failure acco­mpanied with anemia. Russian Journal of Preventive Medi­cine. 2025;(3):80-86
Study of serum cyto­kine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):25-29
Asso­ciations of gene­tic poly­morphisms in key inflammatory response genes with the risk of chro­nic apical periodontitis deve­lopment. Russian Journal of Stomatology. 2025;(2):52-56
Abstract:

OBJECTIVE

To study cytokine status in patients with Alzheimer’s disease (AD).

MATERIAL AND METHODS

The main group of patients with a confirmed AD included 23 patients with a mean age of 69 [66.2; 77.5] years (6 males, 17 females). Data from 163 apparently healthy subjects (data from the archive of the Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency of Russia) were used as a control. A multiplex enzyme immunoassay (xMAP technology) was performed using a FlexMap 3D multiplex flow fluorimeter. Samples were analyzed for the following cytokines: epidermal growth factor (EGF), fibroblast growth factor (FGF-2), eotaxin, transforming growth factor (TGF-α), granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF, GM-CSF), Flt-3L, fractalkine, interferon (IFN)-α2, IFN-γ, GRO, interleukins (IL)-10, -12p40, -12p70, -13, -15, -17A, -1RA, -1α, -9, -1β, -2, -3, -4, -5, -6, -7, -8, IP-10, sCD40L, monocyte chemoattractant protein (MCP)-3,-1, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1a, MIP-1b, tumor necrosis factors (TNF)-α, TNF-β, vascular endothelial growth factor (VEGF).

RESULTS

The median levels of FGF-2, eotaxin, G-CSF, Flt-3L, GM-CSF, fractalkine, IFN-α2, IFN-γ, MCP-3, IL-1RA, -4, -8, TNF-α in the AD group was higher (more than 2-fold) than in the control group. Of note, the median values of eotaxin, G-CSF, GM-CSF, Flt-3L, IFN-α2, IFN-γ, and TNF-α in the AD group exceeded the 90th percentile of those in the control group.

CONCLUSION

The obtained data indicate significant changes in cytokine status in AD, with increased pro-inflammatory cytokines and activated neuroprotective mechanisms.

Keywords:

Alzheimer’s disease
neuroinflammation
cytokines
interleukins

Authors:

Belousov V.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical-Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University)

Bogolepova A.N.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical-Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University)

Katunina E.A.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical-Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University)

Bulanova N.V.

Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency

Mukhin V.E.

Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency

Yudin S.M.

Center for Strategic Planning and Management of Biomedical Health Risks

Received:

06.03.2025

Accepted:

07.03.2025

Close metadata

References:

  1. World Health Organization. Dementia: Key facts. Accessed October 10,2023. Available at: https://www.who.int/news‐room/fact‐sheets/detail/dementia
  2. Rajan KB, Weuve J, Barnes LL, et al. Population estimate of people with clinical AD and mild cognitive impairment in the United States (2020‐2060). Alzheimers Dement. 2021;17(12):1966‐1975. https://doi.org/10.1002/alz.12362
  3. 2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20(5):3708-3821. https://doi.org/10.1002/alz.13809
  4. Nasb M, Tao W, Chen N. Alzheimer’s Disease Puzzle: Delving into Pathogenesis Hypotheses. Aging Dis. 2024;15(1):43-73.  https://doi.org/10.14336/AD.2023.0608
  5. Jorfi M, Maaser-Hecker A, Tanzi RE. The neuroimmune axis of Alzheimer’s disease. Genome Med. 2023;15(1):6.  https://doi.org/10.1186/s13073-023-01155-w
  6. Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y). 2018;4:575-590.  https://doi.org/10.1016/j.trci.2018.06.014
  7. Kempuraj D, Thangavel R, Natteru PA, et al. Neuroinflammation Induces Neurodegeneration. J Neurol Neurosurg Spine. 2016;1(1):1003.
  8. Lobov AV, Pogodina EA, Ivanova PI, et al. Human interferon status. Standardization of the tests and establishing reference values. Russian Journal of Biotherapy. 2022;21(4):30-40. (In Russ.). https://doi.org/10.17650/1726-9784-2022-21-4-30-40
  9. Gizinger O. Rationale for determination of the interferon status in different pathological processes. Vrach. 2019;30(4):15-20. (In Russ.).
  10. Titov VN. The significance of macrophages in the onset of inflammation; the effects of Interleukin-1, Interleukin-6 and the activity of Hypothalamo-hypophysis system (a survey). Klinicheskaja laboratornaja diagnostika. 2003;12:3-12. (In Russ.).
  11. Clinical laboratory diagnostics: national guidelines: in 2 volumes, ed. by Dolgov VV, Menshikov VV. M.: GEOTAR-Media. 2012. (In Russ.).
  12. Galaktionov VG. Immunology. M.: Academy. 2004. (In Russ.).
  13. Jung YJ, Tweedie D, Scerba MT, et al. Repurposing Immunomodulatory imide drugs (IMiDs) in neuropsychiatric and neurodegenerative disorders. Front Neurosci. 2021;15:656921. https://doi.org/10.3389/fnins.2021.656921
  14. Raffaele S, Lombardi M, Verderio C, Fumagalli M. TNF production and release from microglia via extracellular vesicles: impact on brain functions. Cells. 2020;9:2145. https://doi.org/10.3390/cells9102145
  15. Clark IA, Vissel B. Broader insights into understanding tumor necrosis factor and neurodegenerative disease pathogenesis infer new therapeutic approaches. J Alzheimers Dis. 2021;79:931‐948.  https://doi.org/10.3233/JAD-201186
  16. Lecca D, Jung YJ, Scerba MT, et al. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimers Dement. 2022;18(11):2327-2340. https://doi.org/10.1002/alz.12610
  17. Shateri S, Khatami SH, Haghbin Toutounchi A, et al. Plasma cytokines profile in patients with Alzheimer’s and Parkinson’s Disease: a comparative study in terms of inflammation. Int J Neurosci. 2025;135(2):158-167.  https://doi.org/10.1080/00207454.2023.2292951
  18. Roy ER, Wang B, Wan YW, et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest. 2020;130(4):1912-1930. https://doi.org/10.1172/JCI133737
  19. Kann O, Almouhanna F, Chausse B. Interferon γ: a master cytokine in microglia-mediated neural network dysfunction and neurodegeneration. Trends Neurosci. 2022;45(12):913-927.  https://doi.org/10.1016/j.tins.2022.10.007
  20. Cheng Y, Li Z, Kardami E, Loh YP. Neuroprotective effects of LMW and HMW FGF2 against amyloid beta toxicity in primary cultured hippocampal neurons. Neurosci Lett. 2016;632:109-113.  https://doi.org/10.1016/j.neulet.2016.08.031
  21. Chen X, Li Z, Cheng Y, et al. Low and High Molecular Weight FGF-2 Have Differential Effects on Astrocyte Proliferation, but Are Both Protective Against Abeta-Induced Cytotoxicity. Front Mol Neurosci. 2020;12:328.  https://doi.org/10.3389/fnmol.2019.00328
  22. Bettcher BM, Fitch R, Wynn MJ, et al. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer’s disease dementia phenotypes. Alzheimers Dement (Amst). 2016;3:91-97.  https://doi.org/10.1016/j.dadm.2016.05.004
  23. Morgan AR, Touchard S, Leckey C, et al. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimers Dement. 2019;15(6):776-787.  https://doi.org/10.1016/j.jalz.2019.03.007
  24. Pagoni P, Korologou-Linden RS, Howe LD, et al. Causal effects of circulating cytokine concentrations on risk of Alzheimer’s disease and cognitive function. Brain Behav Immun. 2022;104:54-64.  https://doi.org/10.1016/j.bbi.2022.05.006
  25. Su C, Zhao K, Xia H, Xu Y. Peripheral inflammatory biomarkers in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Psychogeriatrics. 2019;19(4):300-309.  https://doi.org/10.1111/psyg.12403
  26. Yeung CHC, Schooling CM. Systemic inflammatory regulators and risk of Alzheimer’s disease: a bidirectional Mendelian-randomization study. Int J Epidemiol. 2021;50(3):829-840.  https://doi.org/10.1093/ije/dyaa241
  27. Rahi V, Jamwal S, Kumar P. Neuroprotection through G-CSF: recent advances and future viewpoints. Pharmacol Rep. 2021;73(2):372-385.  https://doi.org/10.1007/s43440-020-00201-3
  28. Wu CC, Wang IF, Chiang PM, et al. G-CSF-mobilized bone marrow mesenchymal stem cells replenish neural lineages in Alzheimer’s disease mice via CXCR4/SDF-1 Chemotaxis. Mol Neurobiol. 2017;54:6198-6212. https://doi.org/10.1007/s12035-016-0122-x
  29. Spangenberg E, Severson PL, Hohsfield LA, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun. 2019;10:3758. https://doi.org/10.1038/s41467-019-11674-z
  30. Sillau SH, Coughlan C, Ahmed MM, et al. Neuron loss in the brain starts in childhood, increases exponentially with age and is halted by GM-CSF treatment in Alzheimer’s disease. medRxiv. [Preprint]. 2024:2024.07.14.24310223. https://doi.org/10.1101/2024.07.14.24310223
  31. Finneran DJ, Morgan D, Gordon MN, Nash KR. CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model. J Neuroimmune Pharmacol. 2019;14(2):312-325.  https://doi.org/10.1007/s11481-018-9822-5
  32. Cho SH, Sun B, Zhou Y, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem. 2011;286(37):32713-32722. https://doi.org/10.1074/jbc.M111.254268
  33. Finneran DJ, Nash KR. Neuroinflammation and fractalkine signaling in Alzheimer’s disease. J Neuroinflammation. 2019;16(1):30.  https://doi.org/10.1186/s12974-019-1412-9
  34. Araki T, Ikegaya Y, Koyama R.The effects of microglia- and astrocyte-derived factors on neurogenesis in health and disease. Eur J Neurosci. 2021;54(5):5880-5901. https://doi.org/10.1111/ejn.14969
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.